03 October 2016
Dr. Moschetta to present at ESMO Congress
Sarah Cannon Research Institute UK’s Drug Development Unit is proud to announce that Clinical Research Fellow Dr. Michele Moschetta’s research project “Dynamics of Neutrophil to Lymphocyte Ratio (NLR) Predict Effectiveness of PD1/PDL1 Inhibition” has been selected for presentation at the annual European Society for Medical Oncology (“ESMO”) Congress to be held in Copenhagen, Denmark from October 7-11.
In the study, Dr. Moschetta and colleagues found that changes in the ratio between the absolute number of these different types of white blood cells after only two doses of an immunotherapy agent can predict response to the treatment. This easy blood test, if validated in prospective clinical trials, could spare cancer patients to undergo expensive and possibly toxic treatments.
In addition, Dr. Moschetta has been awarded a travel grant and complimentary registration to this prestigious conference.
Download the poster from the link below:
<< Back to News